Research programme: xanthine oxidase inhibitors - Astellas

Drug Profile

Research programme: xanthine oxidase inhibitors - Astellas

Alternative Names: AS 186278-NA; AS 191293-00; AS 1924601-00; AS 1931018-00

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Astellas Pharma
  • Class Carboxylic acids; Nitriles
  • Mechanism of Action Xanthine oxidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Gout; Hyperuricaemia

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Gout in Japan (PO)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Hyperuricaemia in Japan (PO)
  • 26 Aug 2010 Research programme: xanthine oxidase inhibitors - Astellas is available for licensing as of 26 Aug 2010. http://www.astellas.com/en/index.html
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top